Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination Results of the Compass pilot randomised trial
Karen Canfell, Michael Caruana, Val Gebski, Jessica Darlington-Brown, Stella Heley, Julia Brotherton, Dorota Gertig, Chloe J. Jennett, Annabelle Farnsworth, Jeffrey Tan, C. David Wrede, Philip E. Castle, Marion Saville
PLOS Medicine 19 September, 2017
Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination
Brotherton JML, Tabrizi SN, Phillips S, Pyman J, Cornall AM, Lambie N, Anderson L, Cummings M, Payton D, Scurry JP, Newman M, Sharma R, Saville M, Garland SM.
Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30871.
Progress in HPV vaccination in low-and lower-middle- income countries
D. Scott LaMontagne, Paul J.N. Bloem, Julia M.L. Brotherton, Katherine E. Gallagher, Ousseynou Badiane, Cathy Ndiaye
Int J Gynecol Obstet 2017; 138 (Suppl. 1): 7–14
Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance.
Alexis J. Pillsbury, Helen E. Quinn, TaNisha D. Evans, Peter B. McIntyre, Julia M. L. Brotherton.
Clin Infect Dis 2017, 3rd July 2017
Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
Jie-Bin Lew, D James B St John, Xiang-Ming Xu, Marjolein J E Greuter, Michael Caruana, Dayna R Cenin, Emily He, Marion Saville, Paul Grogan, Veerle M H Coupé, Karen Canfell
Lancet Public Health 2017; 2: e331–40, Published Online, June 26, 2017
Addressing Confusion about the Risks and Benefits of Co-Testing versus Human Papillomavirus Tests for Cervical Cancer
Grace Tan, David Hawkes
Acta Cytologica May 5, 2017 DOI:10.1159/000472244
Cost-effectiveness estimates: the need for complete reporting
Jie-Bin Lew, Kate T Simms, Megan A Smith, Marion Saville, Ian Hammond, Karen Canfell
The Lancet Vol 2 May 2017
Self collection Pilot Project improving access to cervical screening for underscreened women
Developed by the University of Melbourne and Victorian Cytology Service Ltd for the Victorian Department of Health and Human Services
Evaluation Report February 2017
Annual Immunisation Coverage Report 2014
Hull BP, Hendry AJ, Dey A, Beard FH, Brotherton JM, McIntyre PB
BP Hull et al. Commun Dis Intell Q Rep 41 (1), E68-E90. 2017 Mar 31.
HPV vaccine coverage is increasing in Australia
Julia ML Brotherton, Karen L Winch, Lisette Bicknell, Genevieve Chappell, Marion Saville
Medical Journal of Australia MJA 206 (6) 3 April 2017 doi: 10.5694/mja16.00958
Time to clinical investigation after a high-grade abnormal Pap test for indigenous and non-indigenous women in Queensland, 2000–2011.
Whop LJ, Baade P, Brotherton JML, Canfell K, Cunningham J, Gertig DM, Lokuge K , Garvey G , Moore SP, Diaz A, O’Connell DL, Valery PC, Roder D, Condon JR.
Med J Aust 2017; 206 (2): 73-77. doi:10.5694/mja16.00255
The population impact of HPV vaccination programmes on HPV infection with the non-vaccine HPV genotypes: a systematic review and meta-analysis.
Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JM, Chow EP, Cummings T, Drolet M, Fairley CK, Garland SM, Kahn JA, Kavanagh K, Markowitz L, Pollock KG, Söderlund-Strand A, Sonnenberg P, Tabrizi SN, Tanton C, Unger E, Thomas SL.
Emerging Infectious Diseases.2016;22(10):1732-1740.
Response to: HPV vaccine and autoimmunity Incidence of new-onset autoimmune disease in girls and women withpre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study
D. Hawkes, W. Wilkinson & R. A. Dunlop
Journal of Internal Medicine 2017 doi:10.1111/joim.12602
Response to "Vaccine-related serious adverse events might have been under-recognised in the pivotal HPV vaccine randomized trial"
Clin Rheumatol. 2017 Mar 25. DOI: http://dx.doi.org/10.1007/s10067-017-3609-6
HPV vaccines: so much learnt, so many more lessons to come
Julia M.L Brotherton
The Lancet Oncology
Opportunities to increase rates of human papillomavirus vaccination in the New South Wales school program through enhanced catch up
Staples C, Butler M, Nguyen J, Durrheim DN, Cashman P, Brotherton JML
Sexual Health 2016. Published online 29 August 2016
Changes to the cervical cancer screening program in Australia
Karen Canfell, Marion Saville, Ian Hammond, Lara Roeske
Medicine Today, May 2016, 17(5), 59-82
The Role of Pejorative Search Terms and Professional Antivaccine Advocates on Search Engine Results for Human Papillomavirus Vaccine
Tracey McDermott, David Hawkes, Ph.D., Joanne Benhamu, R.N.,
Journal of Adolescent Health 58 (2016) 691e694
Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines
Julia M.L. Brotherton, Mark Jit, Patti E. Gravitt, Marc Brisson, Aimee R. Kreimer, Sara I. Pai, Carole Fakhry, Joseph Monsonego and Silvia Franceschi
Int J Cancer. 2016 Aug 1;139(3):510-7. doi: 10.1002/ijc.30063. Epub 2016 Mar 22
Cervical Abnormalities Are More Common among Indigenous than Othe Australian Women: A Retrospective Record-Linkage Study, 2000-2011
Lisa J. Whop, Peter Baade, Gail Garvey, Joan Cunningham, Julia M. L. Brotherton, Kamalini Lokuge, Patricia C. Valery, Dianne L. O’Connell, Karen Canfell, Abbey Diaz, David Roder, Dorota M. Gertig, Suzanne P. Moore, John R. Condon
PLOS ONE, April 11, 2016
The First Comprehensive Report on Indigenous Australian Women's Inequalities in Cervical Screening: A Retrospective Registry Cohort Study in Queensland, Australia (2000-2011)
Lisa J. Whop, Gail Garvey, Peter Baade, Joan Cunningham, Kamalini Lokuge, Julia M. L. Brotherton, Patricia C. Valery, Dianne L. O'Connell, Karen Canfell, Abbey Diaz, David Roder, Dorota Gertig, Suzanne P. Moore and John R. Condon
Cancer: Volume 122, Issue 10, pages 1560–1569, May 15, 2016
Home-based HPV self-sampling improves participation by never-screened and under-screened women: Results from a large randomized trial (iPap) in Australia
Farhana Sultana, Dallas R. English, Julie A. Simpson, Kelly T. Drennan, Robyn Mullins, Julia M.L. Brotherton, C. David Wrede, Stella Heley, Marion Saville and Dorota M. Gertig
International Journal of Cancer Volume 139, Issue 2, pages 281–290, 15 July 2016
Primary Prevention of HPV through Vaccination: Update on Current Global Status
Brotherton JML, Zuber PLF and Bloem PJN
Curr Obst Gynecol Reports 2016. Published online 7 July 2016.
Human papillomavirus vaccination and primary ovarian insufficiency: an association based on ideology rather than evidence
David Hawkes, Jim Buttery
Curr Opin Obstet Gynecol: 2016
Indigenous women on the Queensland Pap Smear Register: the National Indigenous Cervical Screening Project.
Whop LJ, Diaz A, Baade P, Garvey G, Cunningham J, Brotherton JML, Canfell K, Valery PC, O'Connell D, Taylor C, Moore SP, Condon JR.
BMJ Open 2016;6:e009540
Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use
Megan A. Smith, Dorota Gertig, Michaela Hall, Kate Simms, Jie-Bin Lew, Michael Malloy, Marion Saville and Karen Canfell.
BMC Health Services Research (2016) 16:147
Juvenile recurrent respiratory papillomatosis: 10 year audit and Australian prevalance estimates
Novakovic D, Cheng A, Baguley K, Walker P, Harrison H, Soma M, Malloy M, Brotherton JML
The Laryngoscope 2016. 2016 Apr 14.
Monitoring the impact of HPV vaccine in males - considerations and challenges
Brotherton JML, Giuliano A, Markowitz L, Dunne E and Ogilvie G
Papillomavirus Research 2016; 2: 106-111
HPV vaccine impact in Australian women: ready for an HPV-based screening program
Julia ML Brotherton, Dorota M Gertig, Cathryn May, Genevieve Chappell, Marion Saville
MJA 204 (5) 21 March 2016
The acceptability and cost of a home-based chlamydia retesting strategy: findings from the REACT randomised controlled trial
Smith K., Kaldor J., Hocking J., Jamil M., McNulty A., Read P., Bradshaw C., Chen M., Fairley C., Wand H., Worthington K., Blake S., Knight V., Rawlinson W., Saville M., Tabrizi S., Garland S., Donovan B., Guy R.,
BMC Public Health.2016, 16:83 DOI: 10.1186/s12889-016-2727-4
Immunisation coverage annual report, 2013
Hull BP, Dey A, Beard FH, Menzies RI, Brotherton JM and McIntyre PD
Commun Dis Intell Q Rep. 2016 March 31;40(1): E146-69
IPVS Policy statement on safety of HPV vaccines
Garland SM, Stanley M, Brotherton J, Mosckiki A-G, Bhatla N, Kaufmann AM, Sankaranarayanan R and Palefsky J
Papillomavirus Research 2016; 2: 9-10
Women's views on human papillomavirus self-sampling: focus groups to assess acceptability, invitation letters and a test kit in the Australian setting.
Sultana F, Mullins R, Murphy M, English DR, Simpson JA, Drennan KT, Heley S, Wrede CD, Brotherton JM, Saville M, Gertig DM
Sexual Health 2015: 12(4): 279-286
Women’s experience with home-based self- sampling for human papillomavirus testing
Farhana Sultana, Robyn Mullins, Dallas R. English, Julie A. Simpson, Kelly T. Drennan, Stella Heley, C. David Wrede, Julia M. L. Brotherton, Marion Saville and Dorota M. Gertig
BMC Cancer (2015) 15:849
Cervical cancer prevention in Australia: Planning for the future
A. Marion Saville
Cancer Cytopathology, Vol 124, 4, 235-240
HPV prophylactic vaccines: lessons learned from 10 years experience
Future Virology, Vol. 10, No. 8 , Pages 999-1009
Current status of human papillomavirus vaccination
JML Brotherton, GS Ogilvie
Curr Opin Oncol 2015:27(5):399-404
Could one dose of bivalent HPV vaccine prevent cervical cancer?
Julia ML Brotherton
Lancet Oncol 2015:16(7):739-40
Hepatitis B Vaccines and HPV Vaccines Have Been Hailed as Major Public Health Achievements in Preventing Cancer—Could a Schistosomiasis Vaccine be the Third?
Michael H. Hsieh, Julia M. L. Brotherton, Afzal A. Siddiqui
PLOS Neglected Tropical Diseases, May 2015
The effect of making a ‘third dose assumption’ on HPV coverage estimates
Brotherton JML, Winch K.
Australian and New Zealand Journal of Public Health: Volume 39, Issue 2, pages 193–194, April 2015
A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing.
Farhana Sultana, Dorota M. Gertig, C. David Wrede, Dallas R. English, Julie A. Simpson, Kelly T. Drennan, Julia M.L. Brotherton, Gillian Phillips, Stella Heley, Philip E. Castle, Marion Saville.
Journal of Clinical Virology 2015 69 (2015) 210–213
Interim estimates of male human papillomavirus vaccination coverage in the school-based program in Australia
Julia ML Brotherton, Michael R Batchelor, Michelle O Bradley, Scott A Brown, Simone M Duncombe, Dennis Meijer, Lauren E Tracey, Maureen Watson, Rosalind J Webby
Communicable Disease Intelligence 2015 Vol 39, No2
Measuring HPV vaccination coverage in Australia:comparing two alternative population-based denominators
Bianca Barbaro, Julia M.L. Brotherton
Australian and New Zealand Journal of Public Health Aust NZ J Public Health. 2015; Online; 2015
Human papillomavirus prevalence to age 60 years among Australian women prevaccination
Julia M. L. Brotherton, John R. Condon, Peter B. McIntyre, Sepehr N. Tabrizi, Michael Malloy, Suzanne M. Garland and on behalf of the WHINURS study group
Sexual Health, June 2015
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
Mélanie Drolet PhD, Élodie Bénard BSc, Marie-Claude Boily PhD, Hammad Ali PhD, Louise Baandrup MD, Heidi Bauer, MD, Simon Beddows PhD, Jacques Brisson DSc, Julia M L Brotherton BMed, Teresa Cummings BA, Basil Donovan MD, Christopher K Fairley PhD, Elaine W Flagg PhD, Anne M Johnson MD, Jessica A Kahn MD, Kimberley Kavanagh PhD, Susanne K Kjaer MD, Erich V Kliewer PhD, Philippe Lemieux-Mellouki MSc, Lauri Markowitz MD, Aminata Mboup MSc, David Mesher MSc, Linda Niccolai PhD, Jeannie Oliphant FAChSHM, Kevin G Pollock PhD, Kate Soldan PhD, Pam Sonnenberg PhD, Sepehr N Tabrizi PhD, Clare Tanton PhD, Dr Marc Brisson PhD
Lancet Infect Dis 2015: Published Online March 3, 2015
Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia
Julia M. L. Brotherton, A. Marion Saville, Cathryn L. May, Genevieve Chappell, Dorota M. Gertig
Cancer Causes and Control: Published On-Line 25th March 2015
HPV Vaccination: Current Global Status
Julia M.L Brotherton, Paul J.N Bloem
Current Obstetrics and Gynecology Reports 2015
Asking About Human Papillomavirus Vaccination and the usefulness of Registry Validation: A Study of Young Women Recruited Using Facebook
Bharathy Gunasekaran, Yasmin Jayasinghe, Julia M.L. Brotherton, Yeshe Fenner, Elya E. Moore, John D. Wark, Ashley Fletcher, Sepehr N. Tabrizi, Suzanne M. Garland
Vaccine, 33, no. 6., pp. 749-832, 4 Feb 2015.
Two or three doses of human papillomavirus vaccine?
BMJ 2015;350:g7778 (Published 07 January 2015)
Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program
Sarah L. Osborne, Sepehr N. Tabrizi, Julia M.L. Brotherton, Alyssa M. Cornall, John D. Wark, C. David Wrede, Yasmin Jayasinghe, Dorota M. Gertig, Marian K. Pitts, Suzanne M. Garland, on behalf of the VACCINE Study group.
Vaccine, 33, 2015, pp. 201-208.
Estimating human papillomavirus vaccination coverage among young women in Victoria and reasons for non-participation
Brotherton JML, Piers LS, Vaughan L
Sexual Health 2015
HPV.edu study protocol: a cluster randomized controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescents
S. Rachel Skinner1, Cristyn Davies1*, Spring Cooper2, Tanya Stoney3, Helen Marshall4, Jane Jones3, Joanne Collins4, Heidi Hutton3, Adriana Parrella4, Gregory Zimet5, David G. Regan6, Patti Whyte7, Julia M. L. Brotherton8, Peter Richmond3,13, Kirsten McCaffrey9, Suzanne M. Garland10, Julie Leask9, Melissa Kang11, Annette Braunack-Mayer12, John Kaldor6 and Kevin McGeechan9
BMC Public Health 2015
HPV Vaccination: Current Global Status
Brotherton JML and Bloem PJN
Curr Obstet Gynecol Rep 2015
Human Papillomavirus (HPV) Vaccination Safety Assessment: The Methods Matter
Julia M. L. Brotherton, Kristine K Macartney, Etsuko Miyagi and Jim P. Buttery
Intern Med 54: 2531, 2015
Immunisation Coverage, 2012
Brynley P Hull, Aditi Dey, Rob I Menzies, Julia M Brotherton, Peter B McIntyre
Communicable Diseases Intelligence, 38, no. 3, September 2014, pp. E208-31.
Offering HPV vaccination to women treated for high-grade cervical intra-epithelial neoplasia: What do you need to know? [Letter]
Julia ML Brotherton and C David H Wrede
ANZJOG, 2014, 54 (4): 393-396. Article first published online: 13 AUG 2014.
Cervical screening rates for women vaccinated against human papillomavirus
Alison C Budd, Julia M L Brotherton, Dorota M Gertig, Theresa Chau, Kelly T Drennan and Marion Saville
Med J Aust 2014; 201 (5): 279-282
Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
Sepehr N Tabrizi, Julia M L Brotherton, John M Kaldor, S Rachel Skinner, Bette Liu, Deborah Bateson, Kathleen McNamee, Maria Garefalakis, Samuel Phillips, Eleanor Cummins, Michael Malloy, Suzanne M Garland
Lancet Infect Dis, 2014, published online August 6, 2014.
Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never-and under-screened women in Australia
Sultana F, English DR, Simpson JA, Brotherton JML, Drennan K, Mullins R, Heley S, Wrede CD, Saville M, Gertig DM
BMC Cancer, 2014. 14:207. DOI:10.1186/1471-2407-14-207
Rationale and design of REACT: a randomised controlled trial assessing the effectiveness of home-collection to increase chlamydia retesting and detect repeat positive tests
Kirsty S Smith, Jane S Hocking, Marcus Chen, Christopher K Fairley, Anna McNulty, Phillip Read, Catriona S Bradshaw, Sepehr N Tabrizi, Handan Wand, Marion Saville, William Rawlinson, Suzanne M Garland, Basil Donovan, John M Kaldor, and Rebecca Guy
BMC Infectious Diseases, 2014,14:223.
Assessing HPV vaccine coverage in Australia by geography and socioeconomic status: are we protecting those most at risk?
Bianca Barbaro, Julia M.L. Brotherton.
Australian and New Zealand Journal of Public Health, 2014, 38 (4), published online 24 June 2014.
Human Papillomavirus Vaccination
Julia ML Brotherton
British Journal of Hospital Medicine, November 2014, 75, no.11.
Human papillomavirus vaccination: Where are we now?
Journal of Paediatrics and Child Health, 2014, 50 (8), published online 9 June 2014.
Human Papillomavirus control. How are we going with vaccination coverage seven years in
Brotherton JML, Chappell G, Brosi J, Bicknell L, Winch K, Barbaro B, Saville M
Poster presentation Communicable Disease Control Conference - June 2015
Barriers to better three-dose coverage with HPV vaccination in school-based programs.
Watson M, D'Onise K, Lynch J, Brotherton JML
Aust N Z J Public Health, 2014, 38(1):91-92.
High-grade cervical abnormalities and cervical cancer in women following a negative Pap smear with and without an endocervical component: A cohort study with 10 years of follow-up.
Sultana F, English D, Simpson J, Canfell K, Gertig D, Saville M
International Journal of Cancer, 2014, 135 (5), 1 Sept 2014, 1213-19
Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: a case-control study nested within a population-based screening program in Australia
Crowe E, Pandeya N, Brotherton JML, Dobson AJ, Kisely S, Lambert SB, Whiteman DC.
BMJ, 2014, 348:g1458, doi: 10.1136/bmj.g.1458. Published on-line 4 Mar 2014.
HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program
Sepehr N. Tabrizi, Julia M.L. Brotherton
, Matthew P. Stevens, John R. Condon. Peter McIntyre, David Smith, Suzanne M. Garland, on behalf of the WHINURS group
Journal of Clinical Virology, 2014, 60 (3), July 2014, 250-56.
How best to interpret mixed human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia lesions
Callegari ET, Tabrizi SN, Pyman J, Saville M, Cornall AM, Brotherton JML, Garland SM.
Vaccine, 2014, 32, 4082-4088. Published online 22 May 2014
What you need to know about: Human Papillomavirus Vaccination
British Journal of Hospital Medicine 2014; 75(11): C165-C168
Impact of a population-based HPV vaccination program on cervical abnormalities: A data linkage study.
Gertig DM, Brotherton JML, Budd AC, Drennan K, Chappell G, Saville AM.
BMC Medicine, 2013, 11:227, doi:10.1186/1741-7015-11-227
Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: Independent estimates from a nationally representative mobile phone survey.
Brotherton JML, Liu B, Donovan B, Kaldor JM, Saville M
Vaccine, 2014, 32 (5): 592-597, 23 Jan 2014.
Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study)
Young EJ, Tabrizi SN, Brotherton JM, Wark JD, Pyman J, Saville M, Wrede CD, Jayasinghe Y, Tan J, Gertig DM, Pitts M, Garland SM
BMC Cancer 2013 June 19;13:296.
Safety of the quadrivalent human papillomavirus vaccine [editorial].
BMJ, 2013, 347:f5631
Fall in human papillomavirus prevalence following a national vaccination program
Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM
J Infect Dis 2012 Dec 1;206(11): 1645-51.
Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011.
Liu B, Donovan B, Brotherton JML, Saville M, Kaldor JM.
Sex Transm Infect, 2014, 25 February. doi:10.1136/sextrans-2013-051307
Human papillomavirus and head and neck cancers: emerging trends and improving survival [letter to the editor].
Brotherton JML, Stein A, Conway L, Grulich A, Law M, Hocking J.
Aust NZ J Pub Health, 2012, Apr; 36(2): 195-6.
HPV testing in the National Cervical Screening Program, When is it recommended?
Australian Family Physician Vol. 42, No. 7, July 2013: 463:466.
Does human papillomavirus type 16 or 18 prevalence in CIN3 lesions vary by age? An important issue for post vaccination surveillance.
Brotherton JML, Tabrizi SN, Garland SM.
Future Micobiol., 2012, Feb; 7(2), 193-9.
Utility of reports and routine correspondence from the National HPV Vaccination Program Register.
Brotherton JML, Batchelor M, Winch K.
Med J Aust, 2013, 199 (7): 463.
Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach.
Brotherton JML, Murray SL, Hall MA, Andrewartha LK, Banks CA, Meijer D, Pitcher HC, Scully MM, Molchanoff L.
Med J Aust, 2013, 199 (9) :614-617, doi: 10.5694/mja13.10272
Safety of human papillomavirus vaccines: a review
Macartney KK, Chiu C, Georgousakis M, Brotherton JM
Drug Safety 2013 Jun;36(6):393-412.
Adapting the Australian system: is an organized screening program feasible in Malaysia? – an overview of cervical cancer screening in both countries
Rashid RM, Dahlui M, Mohamed M, Gertig D
Asian Pac J Cancer Prev 2013;14(3):2141-6.
Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia
Julia M.L. Brotherton, Michael Malloy, Alison C. Budd, Marion Saville, Kelly T. Drennan, Dorota M. Gertig
Papillomavirus Research Volume 1, December 2015, Pages 59–73
The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.
Smith MA, Lew JB, Walker RJ, Brotherton JML, Nickson C, Canfell K.
Vaccine, 2011, 29 (48), 8 Nov 2011, 9112-22
The Impact of Vaccination and what it means for Cytology Screening
Gertig D, Brotherton J, Saville M.
HPV Today, 2013, July.
Early impact of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study
Brotherton JML, Fridman M, May C, Chappell G, Saville AM, Gertig DM
The Lancet, 2011, 377(9783), 11 Jun 2011, 2085-92.
Human papillomavirus vaccine national catch up program: insights into under notification
Laemmele-Ruff I, Barbaro B, Brotherton JML
Aust Fam Physician, 2013, 42(12): 880-884.
Catching up with the catch- up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register.
Brotherton J, Gertig D, Chappell G, Rowlands L, Saville M.
Commun Dis Intell, Jun 2011, 35(2): 197-201.
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease
Arbyn M, de Sanjose S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL, Denny L, Bornstein J, Abramowitz L, Giuliano A, Tommasino M, Monsonego J
Int J Cancer 2012 Nov 1;131(9):1969-82. EPub 2 July 2012.
Human papillomavirus vaccination and cervical cancer screening by socioeconomic status, Victoria
Barbaro B, Brotherton JML, Gertig D.
Med J Aust, 2012, Apr 16; 196 (7): 445.
Expenditure and resource utilisation for cervical screening in Australia
Lew JB, Howard K, Gertig D, Smith M, Clements M, Nickson C, Shi JF, Dyer S, Lord S, Creighton P, Kang YJ, Tan J, Canfell K
BMC Health Serv Res 2012 Dec 5;12:446.
Why a special issue on anal cancer and what is in it?
Fairley CK, Brotherton JM, Hillman R, Grulich AE.
Sexual Health 2012 Dec;9(6):501-3.
Time for a strategic research response to anal cancer
Grulich AE, Hillman R, Brotherton JM, Fairley CK
Sexual Health 2012 Dec;9(6):628-31.
Human papillomavirus vaccine introduction – the first five years
Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM
Vaccine 2012 Nov 20:30 Suppl 5:F139-48.
Approaches to Monitoring Biological Outcomes for HPV Vaccination: Challenges of Early Adopter Countries
Wong CA, Saraiya M, Hariri S, Eckert L, Howlett RI, Markowitz LE, Brotherton JML et al
Vaccine, 2011, 29 (5): 878-885.
Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia.
Brotherton JM, Mullins RM.
Cancer Epidemiol, 2012, Jun; 36(3): 298-302. Epub 2011 Dec 8.
Mobile phones are a viable option for surveying young Australian women: a comparison of two telephone survey methods.
Liu B, Brotherton JML, Shellard D, Donovan B, Saville M, Kaldor JM.
BMC Medical Research Methodology, 2011, 11: 159, doi:10.1186/1471-2288-11-159
Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study
Georgousakis M, Jayasinghe S, Brotherton J, Gilroy N, Chiu C, Macartney K.
Lancet Infect Dis., 2012, 12 (8), Aug 2012, 627-34.
Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy
Brotherton JML, Kaldor JM, Garland SM.
Sexual Health, 2010, 7(3),310-19.
Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers
Hocking J, Stein A, Conway L, Grulich A, Law M, Brotherton JML.
British Journal of Cancer, 2011, 104, 886-891. Published online 1 Feb 2011.
Human papillomavirus genotype detection from archival papanicolaou-stained cervical tests.
Tabrizi S, Taylor N, McCullough MJ, Phillips G, Wark J, Gertig D, Petersen R, Saville M, Garland S.
Cancer Cytopathology, 2010, 118(6). Published online 12 Oct 2010.
Genital HPV types in Australia [letter].
Brotherton JML, Garland S, Donovan B
Lancet Infect Dis., 2012, Feb;12(2):102-3.
Advancements in the control of genital human papillomavirus infections and related diseases: highlighting Australia’s role.
Garland SM, Brotherton JML, Fairley CK, Gertig DM, Saville M.
Sexual Health, 2010, 7 (3): 227-229.
Human papillomavirus prevalence amongst Indigenous and non-Indigenous Australian women prior to a national HPV vaccination program.
Garland SM*, Brotherton JML*, Condon JR, McIntyre PB, Stevens MP, Smith DW, Tabrizi SN. .[* joint first authors]
BMC Med., 2011, 9(1): 104.
Australia needs a national centre for disease control [letter].
Brotherton JML, Kaldor JM, Saville M.
Med J Aust, 2010, 193 (10): 623-624.
Adolescent and young adult HPV vaccination in Australia: achievements and challenges.
Garland SM, Skinner SR, Brotherton JML
Prev Med, 2011, Oct 1; 53 Suppl 1: S29-35.
Australian HPV Surveillance [letter]
Brotherton JML, Kaldor JM, McIntyre PB.
Vaccine, 2010, 28 (47), 7453-7454.
Trends in anal cancer in Australia, 1982-2005
Jin F , Stein AN, Conway EL, Regan D, Law M, Brotherton JML, Hocking J , Grulich A.
Vaccine, 2011, 29 (12), 9 Mar 2011, 2322-27.
Estimating the incidence of, and treatment patterns for, juvenile onset recurrent respiratory papillomatosis in Australia pre vaccination: a pilot study.
Novakovic D, Cope D, Cheng ALT, Brotherton JML.
Sexual Health, 2010, 7 (3), 19 Aug 2010, 253-61.
Primary prophylactic HPV vaccination programs: future perspective on global impact.
Brotherton JML, Gertig DM.
Expert Rev Anti Infect Ther, Aug 2011, 9 (8): 627-39.
Estimating coverage of the National HPV Vaccination Program: where are we at? [letter] .
Brotherton JML, Mullins R.
Med J Aust, 2009, 191(3):188
Closing editorial: processes, opportunities and challenges after introduction of human papillomavirus vaccine.
Brotherton JML, Fairley CK, Garland SM, Gertig DM, Saville M.
Sexual Health, 2010, 7 (3): 397-398.
Early effect of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study
Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig DM
The Lancet 2011; 377:2085-2092
The incidence of genital warts in Australian women prior to the national vaccination program.
Brotherton JML, Heywood A, Heley S.
Sexual Health, 2009, 6 (3):178-184
National survey of the general practitioner's experience of delivering the National Human Papillomavirus Vaccination Program.
Brotherton JML, Leask J, Jackson C, McCaffery K, Trevena LJ.
Sexual Health, 2010, 7:291-298.
Immunisation coverage annual report, 2011
Hull BP, Dey A, Menzies RI, Brotherton JML and McIntyre PB
Commun Dis Intell Q Rep. 2013 Dec 31;37(4):E291-312
Temporal Associations with Declining Trichomonas vaginalis Diagnosis Rates Among Women in the State of Victoria Australia, 1947 to 2005.
Marrone John, Fairley Christopher, Saville Marion
Sexually Transmitted Diseases, Jun 2008, 35 (6), 572-576
Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia
Gertig DM, Brotherton JML, Saville M
Sexual Health, 2011, 8: 171-178.
“I just signed”: Factors influencing decision making for school-based HPV vaccination.
Cooper Robbins SC, Bernard D, McCaffery K, Brotherton JML, Skinner SR.
Health Psychology, 2010, 29 (6): 618-25.
Abnormal Pap tests after the HPV vaccine.
Heley S, Brotherton J.
Aust Family Physician, 2009, 38 (12): 977-9, Dec 2009.
Outstanding Problems – Glandular Lesions.
Saville Marion, Bloomfield Penny
Cancer Forum, 2008, July 2008; 32 (2).
Fall in human papillomavirus prevalance following a national vaccination program
Tabrizi SN, Brotherton JML, Kaldor JM Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM
Journal of Infectious Diseases. 2012;206(11):1645-51
“Is cancer contagious?”: Australian adolescent girls and their parents: making the most of limited information about HPV and HPV Vaccination.
Cooper Robbins SC, Bernard D, McCaffery K, Brotherton J, Skinner SR.
Vaccine, 2010, 28, issue 19, 26 April 2010, 3398-3408
Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far.
Agorastos T, Chatzigeorgiou K, Brotherton JML, Garland SM.
Vaccine, 2009, 27 (52), 9 Dec 09, 7270-7281.
Human Papillomavirus and Cervical Cancer in Australasia and Oceania: Risk Factors, Epidemiology and Prevention.
Garland Suzanne, Brotherton Julia, Skinner Richard, Pitts Marian, Saville Marion, Mola Glen, Jones Ronald
Vaccine, 2008, 26; Suppl 12, M80-M88, 9 Aug 2008.
Special Issue: Human Papillomavirus Sexual Health Sept 2010, Vol 7, Issue 3